Impact BioMedical Inc. Price & Performance (IBO)

Impact BioMedical's common stock lock-up agreement concluded on March 15, 2025. This 180-day restriction, which began in September 2024, had prevented major stakeholders and executives from selling shares. With the lock-up lifted, market dynamics could shift as these shares become tradable, potentially influencing the stock's liquidity and valuation.1

DSS, Inc. has finalized the sale of its Celios® air purification technology to Impact BioMedical in a $1.15 million equity deal. This strategic move aligns DSS's focus on core growth areas. Celios®, known for its advanced filtration capabilities, enhances Impact BioMedical's portfolio while DSS streamlines its holdings.2

Lifecore Biomedical participated in March's TD Cowen Health Care Conference, KeyBanc Healthcare Forum, and DCAT Week, presenting its strategies and connecting with stakeholders. CEO Paul Josephs highlighted Lifecore’s manufacturing expertise and future growth plans, aiming to strengthen investor relations and expand its market presence.3